Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:43:13.502Z.
Consensus retrieved: 2026-10-06T17:14:07.033Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:43:13.502Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7c85ff734d2850511ecc65d4372fb375f497d0f47939b952c94dba1281e34a39
Forward PE Ratio (N/A) = Dated Quote Price ($1.93) / Consensus Forward EPS ($-1.45)
FORWARD PE RATIO
N/A
Tenax Therapeutics, Inc.
Market Cap
$51.19M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Tenax Therapeutics, Inc. (TENX) | $51.19M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A |
| biote Corp. (BTMD)vs › | $50.28M | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | N/A |
| INmune Bio, Inc. (INMB)vs › | $49.71M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.93, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.45 | $-1.60 – $-1.21 | 7 | n/m |
| 2027-12-31 | $-1.45 | $-1.56 – $-1.32 | 6 | n/m |
| 2028-12-31 | $-1.72 | $-2.15 – $-1.24 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
